Speedel Holds Annual R&D Day
- Extensive data supporting mature and diverse pipeline -
Basel/Switzerland and Bridgewater NJ/USA,
Speedel (SWX: SPPN) today holds its annual Research & Development Day. The event is being held in Zürich, and attended by over 40 investors, analysts and media. The programme highlights Speedel’s achievement in building a mature and diverse pipeline, targeting therapeutic areas with significant unmet medical need and high commercial potential. For the first time Speedel will present results on a new mode of action in cardiovascular treatment, that reduces the production of aldosterone.
Dr. Alice Huxley, CEO, commented: “We are delighted to have the opportunity today to showcase our most recent achievements in R&D at Speedel. We will demonstrate why we have such a strong belief in the clinical value of renin inhibition and are convinced of the commercial potential of SPP 100 (Tekturna/Rasilez), our first source of recurring revenues. Given the depth of scientific and clinical evidence available we plan to continue to develop our own in-house renin inhibitors; remaining the world leader in renin inhibition is a strategic objective for Speedel. I am confident that with our new development programmes in CVM therapies we will find products which will deliver significant benefits to patients. It is our goal to continue to create value though a successful R&D programme as we continue to build Speedel as a top-tier global biopharmaceutical company.”
Today’s programme of speakers from the company’s team is complemented by presentations from Professor Hans R. Brunner and two other key opinion leaders in the fields of hypertension and diabetic kidney disease respectively:
Professor Michel Burnier, Head of the Division of Nephrology and Hypertension Consultation Department of Medicine at the University Hospital of Lausanne, Switzerland and member of the Board of Directors of Speedel, observed: “Diabetic Kidney disease remains a high unmet medical need; as a result of all our recent analysis in efficacy and safety of SPP301, we have learnt and understood more about the mechanisms and how to effectively manage fluid retention. We are now confident in our decision to start a new Phase IIb trial and to progress this drug to the patient”.
Gordon Williams, Professor of Medicine, Harvard Medical School, Boston, Massachusetts, remarked: "To minimise or prevent cardiovascular damage, treat the patient with hypertension, diabetes and heart failure any way you want, but be sure to control the aldosterone’s effect. In reported studies, blocking aldosterone effects improves cardiovascular therapies by reducing cardiovascular morbidity and mortality. A second novel approach would be to reduce the production of aldosterone. This approach represents a new therapeutic strategy with great potential to treat cardiovascular and metabolic diseases.
Forward looking statements
This press release includes forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are based on our current expectations and projections about future events. All statements, other than statements of historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The word “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations described in these forward-looking statements and you should not place undue reliance on them. There can be no assurance that actual results of our research and development activities and our results of operations will not differ materially from these expectations. Factors that could cause actual results to differ from expectations include, among others: our or our partners’ ability to develop safe and efficacious products; our or our partners’ ability to achieve positive results in clinical trials; our or our partners’ ability to obtain marketing approval and market acceptance for our product candidates; our ability to enter into future collaboration and licensing agreements; the impact of competition and technological change; existing and future regulations affecting our business; changes in governmental oversight of pharmaceutical product development; the future scope of our patent coverage or that of third parties; the effects of any future litigation; general economic and business conditions, both internationally and within our industry, including exchange rate variations; and our future financing plans.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.